DOSAGE INDEX / BLEND
BPC-157 + TB-500
Research, reported schedules and supply planning.
Evaluate direct rat combination evidence, limited human knee observations, TB-500 identity and finished-formulation questions for the BPC-157 blend.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 600–1,000 micrograms total per day, divided equally between components
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This page assumes a 1:1 blend. Its 20 mg counterpart uses a different schedule.
Reported example 2
- Amount
- 500–1,500 micrograms total per day, divided equally between components
- Frequency
- Once daily
- Cycle / observation period
- 4–8 weeks in the main overview
- Route / research model
- Subcutaneous
The source also presents an alternative loading approach. Its 10 mg counterpart differs; neither is established here as a human combination regimen.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–14 | 0.6 mg | Daily |
| Days 15–28 | 1 mg | Daily |
| Days 29–56 | 0.6 mg | Daily |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
Source example: 56-day planning window: 39.2 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 10 mg | 4 |
| 20 mg | 2 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- A 2026 rat Achilles-repair study directly compared BPC-157, a material called TB-500, and their combination. It did not find added benefit from combining them. This is evidence about that experiment, not validation of a commercial premixed vial. [1]
- The exploratory study used repaired Achilles tendons in 32 rats and assessed outcomes after four weeks. TB-500 had a significant biomechanical advantage over control; the combined group did not show additional benefit over the individual agents. [1]
- A 2021 retrospective report included four patients receiving BPC-157 with thymosin beta-4; three reported pain improvement. The study lacked a randomized control and did not establish structural healing. Its TB4 description is not an automatic match to every TB-500 product. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 28 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original study
- Original report
- PubMedFurther reading · Listed in reference bibliography.
- Current Pharmaceutical Design (PubMed)Further reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- Annals of the New York Academy of Sciences (PubMed)Further reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- ASIPP / Alternative Therapies in Health and MedicineFurther reading · Listed in reference bibliography.
- Journal of Physiology and Pharmacology (PubMed)Further reading · Listed in reference bibliography.
- Expert Opinion on Biological Therapy (PubMed)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Biomedicines (2022)Further reading · Listed in reference bibliography.
- Current Pharmaceutical Design (2018)Further reading · Listed in reference bibliography.
- Annals of the New York Academy of Sciences (2007)Further reading · Listed in reference bibliography.
- Expert Opinion on Biological Therapy (2018)Further reading · Listed in reference bibliography.
- American Academy of Anti-Aging MedicineNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- International Journal of Clinical Pharmacy (2013)Further reading · Listed in reference bibliography.
- WADA Prohibited List (2024)Further reading · Listed in reference bibliography.
- Arthroscopy (2025)Further reading · Listed in reference bibliography.
- PubMed (2010)Further reading · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.